Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | CRACR2A | Q9BSW2 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13128459 | 1.00 | LMNA (0.40) | LMNAAURKACRACR2AP2RX7MAPK1 | |
| SCHEMBL185692 | 0.86 | LMNA (0.39) | LMNAAURKACRACR2AP2RX7MAPK1 | |
| SCHEMBL2805811 | 0.86 | NAMPT (0.42) | LMNACRACR2AGAANAMPT | |
| SCHEMBL2811096 | 0.82 | NAMPT (0.41) | AURKANAMPT | |
| SCHEMBL2811098 | 0.82 | NAMPT (0.41) | AURKANAMPT | |
| SCHEMBL2809658 | 0.81 | CYP1A2 (0.39) | AURKARAB9ANPC1GAANAMPT | |
| SCHEMBL2804848 | 0.81 | BDKRB1 (0.38) | AURKACTDSP1HDAC1 | |
| SCHEMBL13128468 | 0.81 | BDKRB1 (0.38) | AURKACTDSP1NAMPT | |
| SCHEMBL13128481 | 0.81 | CTDSP1 (0.35) | AURKAP2RX7CTDSP1NAMPT | |
| SCHEMBL2805157 | 0.81 | AURKA (0.39) | LMNAAURKAP2RX7CTDSP1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130131075-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-23 | — | — | US | disclosed |
| US-20100240669-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131075-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | LMNA 2613/4885AURKA 3494/4885CRACR2A 3885/4885 |
| US-20100240669-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | LMNA 2613/4885AURKA 3494/4885CRACR2A 3885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.